Genmab — Marts 2024
-
Enig, @bikube 16:44 - omend påvirkningen nok er mere af mere mental betydning, end økonomisk.
-
The FDA said Friday that it approved Johnson & Johnson's Rybrevant (amivantamab-vmjw) for use in combination with chemotherapy as a front-line treatment for non-small-cell lung cancer (NSCLC). The new indication, based on data from the Phase III PAPILLON trial, is specifically to treat locally advanced or metastatic disease in NSCLC patients with EGFR exon 20 insertion mutations. https://firstwordpharma.com/story/5832710?from=article
-
Transactions in connection with share buy-back program https://www.proinvestor.com/investornyt/1126533/transactions-in-connection-with-share-buy-back-program
-
Jeg kommentere kun på de aktier jeg evt har. Det der sker nu, er spekulation efter min mening + mennesket flokdyrs indstænk.De fleste af os bliver mere og mere overvægtige, men desværre er der også mange der får en mere alvorlig sygdom, som kræft. Jeg vil hellere købe i firmaer der forsker i kræft sygdomme, end mennesker der æder for meget
-
@Sukkeralf - du skrev 2/2 00:12om et studie af GEN1056 som mono eller i kombination med GEN1042. Jeg har ikke kunnet finde noget om dette hos FDA. Hvor fandt du dette studie? PFT:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
